This content is for healthcare professionals only.

This activity is funded by an independent medical education grant from ViiV Healthcare.

This activity is provided by touchIME.

Faculty & Disclosures

Listen on the go

    • View and download resources from this activity to support your learning and share with colleagues. Select a language to continue.

    Downloads
    Download Slides
    Download Slides
    Download Slides
    Download Slides
    Download Slides
    Download Slides
    CORRECT!
    Next question
    Faculty & Disclosures
    Prof. Jens Lundgren

    University of Copenhagen, Hvidovre, Denmark

    Prof. Jens D Lundgren is professor of infectious diseases at the University of Copenhagen, Hvidovre, Denmark and a practising infectious disease specialist. He is also the director of the Centre of Excellence for Health, Immunity and Infections (CHIP). read more

    Prof. Lundgren’s primary research interests are the clinical and public health aspects of HIV infection and its associated infectious and non-infectious morbidities.

    Prof. Lundgren heads PERSIMUNE, a 10-year study funded by the Danish National Research Foundation Centre of Excellence in 2015. He is a member of the Executive Committee of the National Institutes of Health/National Institute of Allergy and Infectious Diseases-funded INSIGHT network, he chairs its scientific steering committee and is co-principal investigator for the START study (CHIP). He is chair of the steering committee for the D:A:D study. He is founder and current member of the steering committee for the EuroSIDA study and founder and current member of the steering committee of the HIV in Europe Initiative, focused on early testing and care for people living with HIV across Europe.

    Prof. Lundgren is also founder of the European AIDS Clinical Society (EACS) non-infectious comorbidity guidelines panel and was awarded the EACS Award for Excellence in HIV Medicine in 2015. He is a member of the American Society of Clinical Investigation and the Association of American Physicians, as well as honorary life-long member of the International Association of Providers of AIDS Care. He is the co-editor-in-chief of HIV Medicine.

    Prof. Jens Lundgren discloses: Research grants from (all fees to institution): Bristol Myers Squibb, Gilead and ViiV Healthcare.
    Prof. Marta Boffito

    Chelsea and Westminster Hospital and Imperial College London, United Kingdom

    Prof. Marta Boffito, MD, PhD, FRCP, is a consultant physician at Chelsea and Westminster Hospital and Imperial College London, UK. read more

    Prof. Boffito is the clinical director of HIV, sexual and gender health, and dermatology at Chelsea and Westminster Hospital, where she runs numerous research projects and clinical trials (including COVID-19 vaccines and treatments). She also consults on complex pharmacological issues, sees patients with HIV (she founded the first HIV over-50-years clinic in London, UK) and teaches HIV medicine, infectious diseases and pharmacology at Imperial College London and in various national and international settings.

    Prof. Boffito trained in Italy, the USA and the UK, and has a special interest in antiviral drug pharmacology from prevention to treatment. In these areas, she contributes to the educational, scientific and guideline-formulation activities of national and international bodies including the British HIV Association and the World Health Organization. She has published over 200 peer-reviewed articles, editorials and reviews.

    She has been involved in capacity-building programmes for resource-limited settings (e.g. Uganda) and is an applicant on numerous successful collaborative international grants.

    Prof. Marta Buffito discloses: Speaker and advisor fees and/or research grants to institution from: AstraZeneca, Cipla, Gilead, GlaxoSmithKline, Janssen, Merck Sharp & Dohme, Moderna, Myland, Novovax, Pfizer, Roche and Valneva.
    Ms Angelina Namiba

    4M Network, United Kingdom

    Originally from Kenya, Ms Angelina Namiba has over 25 years of experience working in the HIV sector. read more

    Throughout her career, Ms Namiba has worked on different initiatives, which include providing one-to-one support to people living with HIV, treatment advocacy, managing service delivery, and facilitating, promoting and advocating for the involvement of women living with HIV in forming and informing local and national strategy and policy.

    Having lived with HIV for 30 years, Ms Namiba is a founding member of the 4M Network of Mentor Mothers, a programme that works with mentor mothers who are living with HIV. The programme trains them to support their peers in their pregnancy journey and for their professional development. She is the lead author of the 4M Mentor Mother Training Manual, and is also co-author of the recently published book Our stories told by us: Celebrating the African contribution to the UK HIV response.

    Ms Namiba also sits on various national and international advisory boards. She is a patron of the National HIV Nurses Association, a lay member of the Women’s Network of the Royal College of Obstetricians and Gynaecologists, a member of the organizing committee of the annual International Workshop onHIV and Women, a community representative for the British HIV Association, and a trustee of the National AIDS Trust, Salamander Trust and SAFE Kenya. She has coauthored various articles in peer-review journals and Joint United Nations Programme on HIV/AIDS reports.

    Ms Angelina Namiba has no interests/relationships or affiliations to disclose in relation to this activity.
    Back to Faculty
    touchINFECTIOUS DISEASES touchINFECTIOUS DISEASES
    Start activity
     
    Videos Take CE/CME Test

    touchPANEL DISCUSSION
    A visually engaging discussion designed to emulate a ‘live’ panel experience and provide clinicians with practical expert insights to address their clinical challenges. Useful tips below will show how to navigate the activity. Close

    Shaping ART around individual needs: Maximizing adherence and quality of life

    Faculty Podcast Featured
    Useful tips
    • Select in the video player controls bar to choose subtitle language. Subtitles available in English, French, German, Italian, Portuguese, Spanish.
    • Downloads including slides are available for this activity in the Toolkit
    Learning Objectives

    After watching this activity, participants should be better able to:

    • Assess the individual needs of newly diagnosed people living with HIV who are initiating ART
    • Apply shared decision making to select the most appropriate first-line ART regimen for people living with HIV
    • Use relevant monitoring strategies for people living with HIV receiving ART, to revise treatment regimen in line with changes in life and preferences
    Overview

    In this activity, two HIV specialists and an advocate for people living with HIV discuss the importance of optimizing antiretroviral therapy (ART) through an individualized approach to care and shared decision making. This discussion is guided by pre-canvassed questions provided by HIV specialists and genitourinary medicine/sexual health specialists.

    This activity has been designed to meet the educational needs of HIV specialists, genitourinary medicine/sexual health specialists, HIV specialist nurses, pharmacists and clinical pharmacists.

    This activity is CE/CME accredited

    To obtain the CE/CME credit(s) from this activity, please complete this post-activity test.

    Claim Credit
    Useful tips
    • Select in the video player controls bar to choose subtitle language. Subtitles available in English, French, German, Italian, Portuguese, Spanish.
    • Downloads including slides are available for this activity in the Toolkit

    You may also be interested in...

    JOURNALS

    Foreword – touchREVIEWS in Infectious Diseases, Volume 3, Issue 1, 2024

    GO TO ARTICLE

    touchEXPERT OPINIONS

    Demystifying virology: The link between the HIV life cycle and ART

    LAUNCH ACTIVITY

    JOURNALS

    Lenacapavir for the Treatment of Heavily Treatment-experienced People with Multi-class Resistant HIV

    GO TO ARTICLE

    touchEXPERT OPINIONS

    Cytomegalovirus in solid organ transplant recipients: Management strategies and emerging therapeutic options

    This activity is CE/CME accredited
    LAUNCH ACTIVITY

    CONFERENCE HUB

    Joseph Domachowske: Phase III MELODY and phase IIb trials investigating nirsevimab for the treatment of respiratory syncytial virus

    GO TO HUB

    CONFERENCE HUB

    Christoph Boesecke: Monkeypox outbreak – Diagnosis, symptoms and guidelines

    GO TO HUB

    Topics covered in this activity

    HIV / Sexually Transmitted Infections / Viral Infections
    REGISTER NOW FOR FREE ACCESS TO
    • 1000+ topical and insightful peer-reviewed journal articles
    • 100+ hours of bite-sized congress highlights
    • 9 major therapy areas packed with the latest scientific advances
    • 150+ specialties offering learn-on-the-go medical education
    • + Concise email updates and newsletters so you never miss out
    Register For Free Now
    This Activity Is Funded By:

    An independent medical education grant from ViiV Healthcare.
    This activity is provided by touchIME.

    Unapproved products or unapproved uses of approved products may be discussed by the faculty; these situations may reflect the approval status in one or more jurisdictions. The presenting faculty have been advised by touchIME to ensure that they disclose any such references made to unlabelled or unapproved use. No endorsement by touchIME of any unapproved products or unapproved uses is either made or implied by mention of these products or uses in touchIME activities. touchIME accepts no responsibility for errors or omissions.

    This content is intended only for healthcare professionals.

    Launch date: 29 June 2023.

    Claim Credit
    touchPANEL DISCUSSION
    Shaping ART around individual needs: Maximizing adherence and quality of life

    You may also be interested in...

    CONFERENCE HUB

    Antiretroviral therapy updates at CROI 2024: emerging treatment strategies in HIV

    GO TO HUB

    JOURNALS

    Foreword – touchREVIEWS in Infectious Diseases, Volume 2, Issue 1, 2023

    GO TO ARTICLE

    JOURNALS

    Bictegravir / Emtricitabine / Tenofovir Alafenomide for the Treatment of HIV / Hepatitis B Virus Co-infection in Patients with Cancer and Transplant Recipients

    GO TO ARTICLE

    touchTALKS

    COVID-19 vaccination: What have we learned and what more can we do to address vaccine inequity in Africa and the Middle East?

    This activity is CE/CME accredited
    LAUNCH ACTIVITY

    touchPANEL DISCUSSION

    Preventing HPV-associated cancer by maximizing vaccine uptake

    This activity is CE/CME accredited
    LAUNCH ACTIVITY

    CONFERENCE HUB

    Joshua Parsons Cohen, EACS 2021: Persistence on Guideline-recommended HIV Treatment

    GO TO HUB
    This Activity Is Funded By:

    An independent medical education grant from ViiV Healthcare.
    This activity is provided by touchIME.

    Unapproved products or unapproved uses of approved products may be discussed by the faculty; these situations may reflect the approval status in one or more jurisdictions. The presenting faculty have been advised by touchIME to ensure that they disclose any such references made to unlabelled or unapproved use. No endorsement by touchIME of any unapproved products or unapproved uses is either made or implied by mention of these products or uses in touchIME activities. touchIME accepts no responsibility for errors or omissions.

    This content is intended only for healthcare professionals.

    Launch date: 29 June 2023.

    Copied to clipboard!
    accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72
    Close Popup